nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—BCHE—multiple sclerosis	0.433	1	CbGaD
Procainamide—SLC22A2—Cladribine—multiple sclerosis	0.0905	0.318	CbGbCtD
Procainamide—SLC22A1—Cladribine—multiple sclerosis	0.0787	0.276	CbGbCtD
Procainamide—BCHE—Triamcinolone—multiple sclerosis	0.072	0.252	CbGbCtD
Procainamide—CYP2D6—Fingolimod—multiple sclerosis	0.0352	0.124	CbGbCtD
Procainamide—SCN3A—spinal nerve—multiple sclerosis	0.0128	0.129	CbGeAlD
Procainamide—CYP2D6—Dexamethasone—multiple sclerosis	0.00859	0.0301	CbGbCtD
Procainamide—SCN11A—peripheral nervous system—multiple sclerosis	0.00685	0.0691	CbGeAlD
Procainamide—SCN11A—nerve—multiple sclerosis	0.00534	0.0539	CbGeAlD
Procainamide—SCN8A—peripheral nervous system—multiple sclerosis	0.00519	0.0524	CbGeAlD
Procainamide—SCN8A—nerve—multiple sclerosis	0.00405	0.0408	CbGeAlD
Procainamide—SCN10A—peripheral nervous system—multiple sclerosis	0.00347	0.035	CbGeAlD
Procainamide—SCN10A—nerve—multiple sclerosis	0.00271	0.0273	CbGeAlD
Procainamide—SCN8A—brainstem—multiple sclerosis	0.00174	0.0175	CbGeAlD
Procainamide—Sunitinib—MERTK—multiple sclerosis	0.0016	0.283	CrCbGaD
Procainamide—DNMT1—retina—multiple sclerosis	0.00144	0.0146	CbGeAlD
Procainamide—SCN11A—spinal cord—multiple sclerosis	0.00142	0.0144	CbGeAlD
Procainamide—SCN1A—brainstem—multiple sclerosis	0.00131	0.0133	CbGeAlD
Procainamide—SCN2A—brainstem—multiple sclerosis	0.0012	0.0122	CbGeAlD
Procainamide—SCN11A—nervous system—multiple sclerosis	0.0012	0.0121	CbGeAlD
Procainamide—SCN11A—central nervous system—multiple sclerosis	0.00116	0.0117	CbGeAlD
Procainamide—SCN8A—spinal cord—multiple sclerosis	0.00108	0.0109	CbGeAlD
Procainamide—Sunitinib—TYK2—multiple sclerosis	0.00108	0.191	CrCbGaD
Procainamide—DNMT1—medulla oblongata—multiple sclerosis	0.00104	0.0105	CbGeAlD
Procainamide—SCN9A—midbrain—multiple sclerosis	0.000973	0.00982	CbGeAlD
Procainamide—DNMT1—midbrain—multiple sclerosis	0.000954	0.00963	CbGeAlD
Procainamide—SCN9A—spinal cord—multiple sclerosis	0.000949	0.00958	CbGeAlD
Procainamide—DNMT1—spinal cord—multiple sclerosis	0.000931	0.00939	CbGeAlD
Procainamide—SCN11A—brain—multiple sclerosis	0.000918	0.00926	CbGeAlD
Procainamide—SCN1A—medulla oblongata—multiple sclerosis	0.000915	0.00924	CbGeAlD
Procainamide—SCN8A—nervous system—multiple sclerosis	0.00091	0.00918	CbGeAlD
Procainamide—SCN8A—central nervous system—multiple sclerosis	0.000876	0.00884	CbGeAlD
Procainamide—SCN8A—cerebellum—multiple sclerosis	0.000856	0.00864	CbGeAlD
Procainamide—ACHE—medulla oblongata—multiple sclerosis	0.000848	0.00856	CbGeAlD
Procainamide—SCN2A—medulla oblongata—multiple sclerosis	0.00084	0.00848	CbGeAlD
Procainamide—SCN1A—midbrain—multiple sclerosis	0.000837	0.00844	CbGeAlD
Procainamide—SCN1A—spinal cord—multiple sclerosis	0.000816	0.00824	CbGeAlD
Procainamide—DNMT1—nervous system—multiple sclerosis	0.000784	0.00791	CbGeAlD
Procainamide—SCN7A—brain—multiple sclerosis	0.00078	0.00788	CbGeAlD
Procainamide—ACHE—midbrain—multiple sclerosis	0.000775	0.00782	CbGeAlD
Procainamide—SCN2A—midbrain—multiple sclerosis	0.000768	0.00775	CbGeAlD
Procainamide—ACHE—spinal cord—multiple sclerosis	0.000756	0.00763	CbGeAlD
Procainamide—DNMT1—central nervous system—multiple sclerosis	0.000755	0.00762	CbGeAlD
Procainamide—Oxybuprocaine—BCHE—multiple sclerosis	0.00075	0.133	CrCbGaD
Procainamide—SCN2A—spinal cord—multiple sclerosis	0.000749	0.00756	CbGeAlD
Procainamide—SCN3A—medulla oblongata—multiple sclerosis	0.000738	0.00745	CbGeAlD
Procainamide—DNMT1—cerebellum—multiple sclerosis	0.000738	0.00745	CbGeAlD
Procainamide—SCN10A—spinal cord—multiple sclerosis	0.000722	0.00729	CbGeAlD
Procainamide—SCN4A—nervous system—multiple sclerosis	0.000713	0.0072	CbGeAlD
Procainamide—Chloroprocaine—BCHE—multiple sclerosis	0.000697	0.124	CrCbGaD
Procainamide—SCN8A—brain—multiple sclerosis	0.000695	0.00702	CbGeAlD
Procainamide—SCN1A—nervous system—multiple sclerosis	0.000688	0.00694	CbGeAlD
Procainamide—SCN4A—central nervous system—multiple sclerosis	0.000687	0.00693	CbGeAlD
Procainamide—SCN3A—midbrain—multiple sclerosis	0.000675	0.00681	CbGeAlD
Procainamide—Procaine—BCHE—multiple sclerosis	0.000665	0.118	CrCbGaD
Procainamide—Cinchocaine—BCHE—multiple sclerosis	0.000665	0.118	CrCbGaD
Procainamide—SCN1A—central nervous system—multiple sclerosis	0.000662	0.00668	CbGeAlD
Procainamide—SCN3A—spinal cord—multiple sclerosis	0.000658	0.00665	CbGeAlD
Procainamide—SCN1A—cerebellum—multiple sclerosis	0.000647	0.00653	CbGeAlD
Procainamide—SCN2A—nervous system—multiple sclerosis	0.000631	0.00637	CbGeAlD
Procainamide—SCN9A—brain—multiple sclerosis	0.000611	0.00617	CbGeAlD
Procainamide—SCN10A—nervous system—multiple sclerosis	0.000609	0.00614	CbGeAlD
Procainamide—SCN2A—central nervous system—multiple sclerosis	0.000608	0.00613	CbGeAlD
Procainamide—ACHE—cerebellum—multiple sclerosis	0.000599	0.00605	CbGeAlD
Procainamide—DNMT1—brain—multiple sclerosis	0.000599	0.00605	CbGeAlD
Procainamide—BCHE—brainstem—multiple sclerosis	0.000598	0.00603	CbGeAlD
Procainamide—SCN2A—cerebellum—multiple sclerosis	0.000594	0.006	CbGeAlD
Procainamide—SLC22A5—retina—multiple sclerosis	0.000592	0.00597	CbGeAlD
Procainamide—SCN10A—central nervous system—multiple sclerosis	0.000586	0.00592	CbGeAlD
Procainamide—SLC22A4—spinal cord—multiple sclerosis	0.000577	0.00582	CbGeAlD
Procainamide—SCN3A—nervous system—multiple sclerosis	0.000555	0.0056	CbGeAlD
Procainamide—SCN5A—nervous system—multiple sclerosis	0.000553	0.00558	CbGeAlD
Procainamide—SCN4A—brain—multiple sclerosis	0.000545	0.0055	CbGeAlD
Procainamide—SCN3A—central nervous system—multiple sclerosis	0.000534	0.00539	CbGeAlD
Procainamide—SCN5A—central nervous system—multiple sclerosis	0.000533	0.00538	CbGeAlD
Procainamide—SCN1A—brain—multiple sclerosis	0.000526	0.00531	CbGeAlD
Procainamide—SCN3A—cerebellum—multiple sclerosis	0.000522	0.00527	CbGeAlD
Procainamide—ACHE—brain—multiple sclerosis	0.000487	0.00491	CbGeAlD
Procainamide—SCN2A—brain—multiple sclerosis	0.000482	0.00487	CbGeAlD
Procainamide—CHRM2—nervous system—multiple sclerosis	0.000471	0.00475	CbGeAlD
Procainamide—SCN10A—brain—multiple sclerosis	0.000465	0.0047	CbGeAlD
Procainamide—SLC22A1—nervous system—multiple sclerosis	0.000463	0.00467	CbGeAlD
Procainamide—SLC22A4—cerebellum—multiple sclerosis	0.000457	0.00461	CbGeAlD
Procainamide—CHRM2—central nervous system—multiple sclerosis	0.000453	0.00458	CbGeAlD
Procainamide—SLC22A1—central nervous system—multiple sclerosis	0.000445	0.0045	CbGeAlD
Procainamide—SLC22A3—nervous system—multiple sclerosis	0.000442	0.00446	CbGeAlD
Procainamide—Renal failure—Mitoxantrone—multiple sclerosis	0.000429	0.00402	CcSEcCtD
Procainamide—SLC22A5—medulla oblongata—multiple sclerosis	0.000428	0.00432	CbGeAlD
Procainamide—Confusional state—Cladribine—multiple sclerosis	0.000427	0.004	CcSEcCtD
Procainamide—SLC22A3—central nervous system—multiple sclerosis	0.000426	0.0043	CbGeAlD
Procainamide—SCN3A—brain—multiple sclerosis	0.000424	0.00428	CbGeAlD
Procainamide—SCN5A—brain—multiple sclerosis	0.000423	0.00427	CbGeAlD
Procainamide—Oliguria—Methotrexate—multiple sclerosis	0.000422	0.00395	CcSEcCtD
Procainamide—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.000417	0.0039	CcSEcCtD
Procainamide—BCHE—medulla oblongata—multiple sclerosis	0.000417	0.00421	CbGeAlD
Procainamide—Thrombocytopenia—Cladribine—multiple sclerosis	0.000415	0.00388	CcSEcCtD
Procainamide—Hepatic enzyme increased—Methotrexate—multiple sclerosis	0.000411	0.00385	CcSEcCtD
Procainamide—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.000408	0.00382	CcSEcCtD
Procainamide—Cardiac arrest—Triamcinolone—multiple sclerosis	0.000407	0.00381	CcSEcCtD
Procainamide—Cardiac arrest—Methylprednisolone—multiple sclerosis	0.000406	0.0038	CcSEcCtD
Procainamide—Anorexia—Cladribine—multiple sclerosis	0.000404	0.00378	CcSEcCtD
Procainamide—Bradycardia—Mitoxantrone—multiple sclerosis	0.000399	0.00374	CcSEcCtD
Procainamide—Vasculitis—Methotrexate—multiple sclerosis	0.000399	0.00373	CcSEcCtD
Procainamide—Cardiac failure—Dexamethasone—multiple sclerosis	0.000398	0.00372	CcSEcCtD
Procainamide—Cardiac failure—Betamethasone—multiple sclerosis	0.000398	0.00372	CcSEcCtD
Procainamide—Hypotension—Cladribine—multiple sclerosis	0.000396	0.00371	CcSEcCtD
Procainamide—Lethargy—Dexamethasone—multiple sclerosis	0.000396	0.00371	CcSEcCtD
Procainamide—Lethargy—Betamethasone—multiple sclerosis	0.000396	0.00371	CcSEcCtD
Procainamide—CYP2D6—brainstem—multiple sclerosis	0.000396	0.004	CbGeAlD
Procainamide—Ill-defined disorder—Azathioprine—multiple sclerosis	0.000392	0.00367	CcSEcCtD
Procainamide—SLC22A5—midbrain—multiple sclerosis	0.000391	0.00395	CbGeAlD
Procainamide—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000386	0.00361	CcSEcCtD
Procainamide—SLC22A5—spinal cord—multiple sclerosis	0.000382	0.00385	CbGeAlD
Procainamide—BCHE—midbrain—multiple sclerosis	0.000381	0.00384	CbGeAlD
Procainamide—Malaise—Azathioprine—multiple sclerosis	0.000381	0.00356	CcSEcCtD
Procainamide—Psychotic disorder—Dexamethasone—multiple sclerosis	0.000379	0.00355	CcSEcCtD
Procainamide—Psychotic disorder—Betamethasone—multiple sclerosis	0.000379	0.00355	CcSEcCtD
Procainamide—BCHE—spinal cord—multiple sclerosis	0.000372	0.00375	CbGeAlD
Procainamide—SLC22A4—brain—multiple sclerosis	0.000371	0.00375	CbGeAlD
Procainamide—Cardiac arrest—Betamethasone—multiple sclerosis	0.000369	0.00345	CcSEcCtD
Procainamide—Cardiac arrest—Dexamethasone—multiple sclerosis	0.000369	0.00345	CcSEcCtD
Procainamide—Decreased appetite—Cladribine—multiple sclerosis	0.000368	0.00345	CcSEcCtD
Procainamide—CHRM2—brain—multiple sclerosis	0.00036	0.00363	CbGeAlD
Procainamide—Arthralgia—Azathioprine—multiple sclerosis	0.000359	0.00336	CcSEcCtD
Procainamide—Myalgia—Azathioprine—multiple sclerosis	0.000359	0.00336	CcSEcCtD
Procainamide—Discomfort—Azathioprine—multiple sclerosis	0.000355	0.00332	CcSEcCtD
Procainamide—SLC22A1—brain—multiple sclerosis	0.000354	0.00357	CbGeAlD
Procainamide—Chills—Mitoxantrone—multiple sclerosis	0.000352	0.00329	CcSEcCtD
Procainamide—Feeling abnormal—Cladribine—multiple sclerosis	0.000349	0.00327	CcSEcCtD
Procainamide—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000347	0.00324	CcSEcCtD
Procainamide—Cardiac failure—Prednisone—multiple sclerosis	0.000346	0.00324	CcSEcCtD
Procainamide—Lethargy—Prednisone—multiple sclerosis	0.000345	0.00323	CcSEcCtD
Procainamide—DNMT1—Budesonide—Methylprednisolone—multiple sclerosis	0.000341	0.0867	CbGdCrCtD
Procainamide—SLC22A3—brain—multiple sclerosis	0.000338	0.00341	CbGeAlD
Procainamide—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000337	0.00316	CcSEcCtD
Procainamide—Urticaria—Cladribine—multiple sclerosis	0.000337	0.00315	CcSEcCtD
Procainamide—DNMT1—Budesonide—Betamethasone—multiple sclerosis	0.000336	0.0853	CbGdCrCtD
Procainamide—DNMT1—Budesonide—Dexamethasone—multiple sclerosis	0.000336	0.0853	CbGdCrCtD
Procainamide—Abdominal pain—Cladribine—multiple sclerosis	0.000335	0.00314	CcSEcCtD
Procainamide—Body temperature increased—Cladribine—multiple sclerosis	0.000335	0.00314	CcSEcCtD
Procainamide—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000334	0.00313	CcSEcCtD
Procainamide—Psychotic disorder—Prednisone—multiple sclerosis	0.00033	0.00309	CcSEcCtD
Procainamide—DNMT1—Budesonide—Triamcinolone—multiple sclerosis	0.000328	0.0833	CbGdCrCtD
Procainamide—Bradycardia—Prednisolone—multiple sclerosis	0.000327	0.00307	CcSEcCtD
Procainamide—Hypotension—Azathioprine—multiple sclerosis	0.000322	0.00301	CcSEcCtD
Procainamide—Cardiac arrest—Prednisone—multiple sclerosis	0.000321	0.00301	CcSEcCtD
Procainamide—Ill-defined disorder—Mitoxantrone—multiple sclerosis	0.000317	0.00296	CcSEcCtD
Procainamide—Hepatic failure—Methotrexate—multiple sclerosis	0.000314	0.00294	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000314	0.00294	CcSEcCtD
Procainamide—BCHE—nervous system—multiple sclerosis	0.000313	0.00316	CbGeAlD
Procainamide—Hypersensitivity—Cladribine—multiple sclerosis	0.000312	0.00292	CcSEcCtD
Procainamide—DNMT1—Budesonide—Prednisone—multiple sclerosis	0.000311	0.0791	CbGdCrCtD
Procainamide—Malaise—Mitoxantrone—multiple sclerosis	0.000308	0.00288	CcSEcCtD
Procainamide—Asthenia—Cladribine—multiple sclerosis	0.000304	0.00285	CcSEcCtD
Procainamide—DNMT1—Budesonide—Prednisolone—multiple sclerosis	0.000304	0.0772	CbGdCrCtD
Procainamide—SLC22A5—cerebellum—multiple sclerosis	0.000303	0.00305	CbGeAlD
Procainamide—BCHE—central nervous system—multiple sclerosis	0.000301	0.00304	CbGeAlD
Procainamide—Bradycardia—Triamcinolone—multiple sclerosis	0.000301	0.00282	CcSEcCtD
Procainamide—Bradycardia—Methylprednisolone—multiple sclerosis	0.000301	0.00281	CcSEcCtD
Procainamide—Pruritus—Cladribine—multiple sclerosis	0.0003	0.00281	CcSEcCtD
Procainamide—Convulsion—Mitoxantrone—multiple sclerosis	0.000296	0.00277	CcSEcCtD
Procainamide—BCHE—cerebellum—multiple sclerosis	0.000295	0.00297	CbGeAlD
Procainamide—Hallucination—Methylprednisolone—multiple sclerosis	0.000294	0.00275	CcSEcCtD
Procainamide—Arthralgia—Mitoxantrone—multiple sclerosis	0.000291	0.00272	CcSEcCtD
Procainamide—Myalgia—Mitoxantrone—multiple sclerosis	0.000291	0.00272	CcSEcCtD
Procainamide—Diarrhoea—Cladribine—multiple sclerosis	0.00029	0.00271	CcSEcCtD
Procainamide—Lethargy—Methotrexate—multiple sclerosis	0.000288	0.0027	CcSEcCtD
Procainamide—Discomfort—Mitoxantrone—multiple sclerosis	0.000287	0.00269	CcSEcCtD
Procainamide—Feeling abnormal—Azathioprine—multiple sclerosis	0.000284	0.00266	CcSEcCtD
Procainamide—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000282	0.00264	CcSEcCtD
Procainamide—Confusional state—Mitoxantrone—multiple sclerosis	0.000281	0.00263	CcSEcCtD
Procainamide—Dizziness—Cladribine—multiple sclerosis	0.00028	0.00262	CcSEcCtD
Procainamide—Shock—Mitoxantrone—multiple sclerosis	0.000274	0.00257	CcSEcCtD
Procainamide—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000274	0.00256	CcSEcCtD
Procainamide—Bradycardia—Betamethasone—multiple sclerosis	0.000273	0.00256	CcSEcCtD
Procainamide—Bradycardia—Dexamethasone—multiple sclerosis	0.000273	0.00256	CcSEcCtD
Procainamide—Neutropenia—Prednisone—multiple sclerosis	0.000273	0.00256	CcSEcCtD
Procainamide—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000273	0.00255	CcSEcCtD
Procainamide—Abdominal pain—Azathioprine—multiple sclerosis	0.000272	0.00255	CcSEcCtD
Procainamide—Body temperature increased—Azathioprine—multiple sclerosis	0.000272	0.00255	CcSEcCtD
Procainamide—Vomiting—Cladribine—multiple sclerosis	0.000269	0.00252	CcSEcCtD
Procainamide—Hallucination—Dexamethasone—multiple sclerosis	0.000267	0.0025	CcSEcCtD
Procainamide—Hallucination—Betamethasone—multiple sclerosis	0.000267	0.0025	CcSEcCtD
Procainamide—Anorexia—Mitoxantrone—multiple sclerosis	0.000266	0.00249	CcSEcCtD
Procainamide—Hypotension—Mitoxantrone—multiple sclerosis	0.00026	0.00244	CcSEcCtD
Procainamide—Ill-defined disorder—Prednisolone—multiple sclerosis	0.00026	0.00243	CcSEcCtD
Procainamide—Depression—Prednisone—multiple sclerosis	0.00026	0.00243	CcSEcCtD
Procainamide—Angioedema—Prednisolone—multiple sclerosis	0.000256	0.0024	CcSEcCtD
Procainamide—Hypersensitivity—Azathioprine—multiple sclerosis	0.000254	0.00238	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000254	0.00238	CcSEcCtD
Procainamide—Malaise—Prednisolone—multiple sclerosis	0.000253	0.00236	CcSEcCtD
Procainamide—Dysgeusia—Triamcinolone—multiple sclerosis	0.000252	0.00236	CcSEcCtD
Procainamide—Nausea—Cladribine—multiple sclerosis	0.000252	0.00236	CcSEcCtD
Procainamide—SLC22A5—brain—multiple sclerosis	0.000246	0.00248	CbGeAlD
Procainamide—Convulsion—Prednisolone—multiple sclerosis	0.000243	0.00227	CcSEcCtD
Procainamide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000242	0.00227	CcSEcCtD
Procainamide—Eosinophilia—Methotrexate—multiple sclerosis	0.000242	0.00226	CcSEcCtD
Procainamide—BCHE—brain—multiple sclerosis	0.000239	0.00242	CbGeAlD
Procainamide—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000239	0.00224	CcSEcCtD
Procainamide—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000238	0.00223	CcSEcCtD
Procainamide—Bradycardia—Prednisone—multiple sclerosis	0.000238	0.00223	CcSEcCtD
Procainamide—Diarrhoea—Azathioprine—multiple sclerosis	0.000236	0.00221	CcSEcCtD
Procainamide—Discomfort—Prednisolone—multiple sclerosis	0.000236	0.0022	CcSEcCtD
Procainamide—Angioedema—Triamcinolone—multiple sclerosis	0.000235	0.0022	CcSEcCtD
Procainamide—Angioedema—Methylprednisolone—multiple sclerosis	0.000235	0.0022	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000234	0.00219	CcSEcCtD
Procainamide—Hallucination—Prednisone—multiple sclerosis	0.000233	0.00218	CcSEcCtD
Procainamide—Malaise—Triamcinolone—multiple sclerosis	0.000232	0.00217	CcSEcCtD
Procainamide—Malaise—Methylprednisolone—multiple sclerosis	0.000232	0.00217	CcSEcCtD
Procainamide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00023	0.00215	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—multiple sclerosis	0.000228	0.00214	CcSEcCtD
Procainamide—Dizziness—Azathioprine—multiple sclerosis	0.000228	0.00213	CcSEcCtD
Procainamide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000228	0.00213	CcSEcCtD
Procainamide—Shock—Prednisolone—multiple sclerosis	0.000225	0.0021	CcSEcCtD
Procainamide—Convulsion—Triamcinolone—multiple sclerosis	0.000223	0.00209	CcSEcCtD
Procainamide—Convulsion—Methylprednisolone—multiple sclerosis	0.000223	0.00208	CcSEcCtD
Procainamide—Urticaria—Mitoxantrone—multiple sclerosis	0.000221	0.00207	CcSEcCtD
Procainamide—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00022	0.00206	CcSEcCtD
Procainamide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00022	0.00206	CcSEcCtD
Procainamide—Myalgia—Triamcinolone—multiple sclerosis	0.000219	0.00205	CcSEcCtD
Procainamide—Vomiting—Azathioprine—multiple sclerosis	0.000219	0.00205	CcSEcCtD
Procainamide—Arthralgia—Methylprednisolone—multiple sclerosis	0.000219	0.00205	CcSEcCtD
Procainamide—Myalgia—Methylprednisolone—multiple sclerosis	0.000219	0.00205	CcSEcCtD
Procainamide—Depression—Methotrexate—multiple sclerosis	0.000217	0.00203	CcSEcCtD
Procainamide—Flushing—Prednisone—multiple sclerosis	0.000217	0.00203	CcSEcCtD
Procainamide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000217	0.00203	CcSEcCtD
Procainamide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000217	0.00203	CcSEcCtD
Procainamide—Discomfort—Triamcinolone—multiple sclerosis	0.000217	0.00203	CcSEcCtD
Procainamide—Discomfort—Methylprednisolone—multiple sclerosis	0.000216	0.00202	CcSEcCtD
Procainamide—Renal failure—Methotrexate—multiple sclerosis	0.000214	0.002	CcSEcCtD
Procainamide—Angioedema—Dexamethasone—multiple sclerosis	0.000214	0.002	CcSEcCtD
Procainamide—Angioedema—Betamethasone—multiple sclerosis	0.000214	0.002	CcSEcCtD
Procainamide—Confusional state—Methylprednisolone—multiple sclerosis	0.000211	0.00198	CcSEcCtD
Procainamide—Malaise—Dexamethasone—multiple sclerosis	0.000211	0.00197	CcSEcCtD
Procainamide—Malaise—Betamethasone—multiple sclerosis	0.000211	0.00197	CcSEcCtD
Procainamide—DNMT1—Betamethasone—Methylprednisolone—multiple sclerosis	0.000209	0.053	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000209	0.053	CbGdCrCtD
Procainamide—CYP2D6—nervous system—multiple sclerosis	0.000207	0.00209	CbGeAlD
Procainamide—Shock—Triamcinolone—multiple sclerosis	0.000207	0.00194	CcSEcCtD
Procainamide—Shock—Methylprednisolone—multiple sclerosis	0.000206	0.00193	CcSEcCtD
Procainamide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000205	0.00192	CcSEcCtD
Procainamide—DNMT1—Betamethasone—Dexamethasone—multiple sclerosis	0.000205	0.0522	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Betamethasone—multiple sclerosis	0.000205	0.0522	CbGdCrCtD
Procainamide—Nausea—Azathioprine—multiple sclerosis	0.000205	0.00192	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000203	0.0019	CcSEcCtD
Procainamide—Convulsion—Betamethasone—multiple sclerosis	0.000202	0.0019	CcSEcCtD
Procainamide—Convulsion—Dexamethasone—multiple sclerosis	0.000202	0.0019	CcSEcCtD
Procainamide—DNMT1—Dexamethasone—Triamcinolone—multiple sclerosis	0.000201	0.051	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Triamcinolone—multiple sclerosis	0.000201	0.051	CbGdCrCtD
Procainamide—Asthenia—Mitoxantrone—multiple sclerosis	0.0002	0.00187	CcSEcCtD
Procainamide—CYP2D6—central nervous system—multiple sclerosis	0.0002	0.00202	CbGeAlD
Procainamide—Myalgia—Dexamethasone—multiple sclerosis	0.000199	0.00186	CcSEcCtD
Procainamide—Myalgia—Betamethasone—multiple sclerosis	0.000199	0.00186	CcSEcCtD
Procainamide—Discomfort—Dexamethasone—multiple sclerosis	0.000197	0.00184	CcSEcCtD
Procainamide—Discomfort—Betamethasone—multiple sclerosis	0.000197	0.00184	CcSEcCtD
Procainamide—Hypotension—Methylprednisolone—multiple sclerosis	0.000196	0.00183	CcSEcCtD
Procainamide—CYP2D6—cerebellum—multiple sclerosis	0.000195	0.00197	CbGeAlD
Procainamide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000191	0.00179	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000191	0.00179	CcSEcCtD
Procainamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000191	0.00178	CcSEcCtD
Procainamide—DNMT1—Dexamethasone—Prednisone—multiple sclerosis	0.00019	0.0484	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Prednisone—multiple sclerosis	0.00019	0.0484	CbGdCrCtD
Procainamide—Ill-defined disorder—Prednisone—multiple sclerosis	0.000189	0.00177	CcSEcCtD
Procainamide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000188	0.00176	CcSEcCtD
Procainamide—Shock—Betamethasone—multiple sclerosis	0.000188	0.00176	CcSEcCtD
Procainamide—Shock—Dexamethasone—multiple sclerosis	0.000188	0.00176	CcSEcCtD
Procainamide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000187	0.00175	CcSEcCtD
Procainamide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000187	0.00175	CcSEcCtD
Procainamide—Angioedema—Prednisone—multiple sclerosis	0.000186	0.00174	CcSEcCtD
Procainamide—DNMT1—Dexamethasone—Prednisolone—multiple sclerosis	0.000186	0.0472	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Prednisolone—multiple sclerosis	0.000186	0.0472	CbGdCrCtD
Procainamide—Probenecid—ALB—multiple sclerosis	0.000184	0.0326	CrCbGaD
Procainamide—Malaise—Prednisone—multiple sclerosis	0.000184	0.00172	CcSEcCtD
Procainamide—Anorexia—Betamethasone—multiple sclerosis	0.000182	0.0017	CcSEcCtD
Procainamide—Anorexia—Dexamethasone—multiple sclerosis	0.000182	0.0017	CcSEcCtD
Procainamide—Urticaria—Prednisolone—multiple sclerosis	0.000182	0.0017	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—multiple sclerosis	0.000181	0.0017	CcSEcCtD
Procainamide—Hypotension—Dexamethasone—multiple sclerosis	0.000178	0.00167	CcSEcCtD
Procainamide—Hypotension—Betamethasone—multiple sclerosis	0.000178	0.00167	CcSEcCtD
Procainamide—Vomiting—Mitoxantrone—multiple sclerosis	0.000177	0.00166	CcSEcCtD
Procainamide—Convulsion—Prednisone—multiple sclerosis	0.000176	0.00165	CcSEcCtD
Procainamide—Chills—Methotrexate—multiple sclerosis	0.000175	0.00164	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000174	0.00163	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000174	0.00163	CcSEcCtD
Procainamide—Arthralgia—Prednisone—multiple sclerosis	0.000173	0.00162	CcSEcCtD
Procainamide—Myalgia—Prednisone—multiple sclerosis	0.000173	0.00162	CcSEcCtD
Procainamide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000173	0.00162	CcSEcCtD
Procainamide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000173	0.00162	CcSEcCtD
Procainamide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000171	0.00161	CcSEcCtD
Procainamide—Discomfort—Prednisone—multiple sclerosis	0.000171	0.0016	CcSEcCtD
Procainamide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000168	0.00158	CcSEcCtD
Procainamide—Urticaria—Triamcinolone—multiple sclerosis	0.000167	0.00156	CcSEcCtD
Procainamide—Urticaria—Methylprednisolone—multiple sclerosis	0.000167	0.00156	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—multiple sclerosis	0.000167	0.00156	CcSEcCtD
Procainamide—Body temperature increased—Triamcinolone—multiple sclerosis	0.000166	0.00156	CcSEcCtD
Procainamide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000166	0.00155	CcSEcCtD
Procainamide—Decreased appetite—Betamethasone—multiple sclerosis	0.000166	0.00155	CcSEcCtD
Procainamide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000166	0.00155	CcSEcCtD
Procainamide—Nausea—Mitoxantrone—multiple sclerosis	0.000165	0.00155	CcSEcCtD
Procainamide—Shock—Prednisone—multiple sclerosis	0.000163	0.00153	CcSEcCtD
Procainamide—CYP2D6—brain—multiple sclerosis	0.000159	0.0016	CbGeAlD
Procainamide—Anorexia—Prednisone—multiple sclerosis	0.000158	0.00148	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000158	0.00148	CcSEcCtD
Procainamide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000157	0.00147	CcSEcCtD
Procainamide—Feeling abnormal—Betamethasone—multiple sclerosis	0.000157	0.00147	CcSEcCtD
Procainamide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000156	0.00146	CcSEcCtD
Procainamide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000156	0.00146	CcSEcCtD
Procainamide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000155	0.00145	CcSEcCtD
Procainamide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000155	0.00145	CcSEcCtD
Procainamide—Malaise—Methotrexate—multiple sclerosis	0.000153	0.00144	CcSEcCtD
Procainamide—Urticaria—Betamethasone—multiple sclerosis	0.000152	0.00142	CcSEcCtD
Procainamide—Urticaria—Dexamethasone—multiple sclerosis	0.000152	0.00142	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000151	0.00142	CcSEcCtD
Procainamide—Dizziness—Prednisolone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Procainamide—Asthenia—Triamcinolone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Procainamide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Procainamide—Abdominal pain—Betamethasone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Procainamide—Body temperature increased—Dexamethasone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Procainamide—Body temperature increased—Betamethasone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Procainamide—Asthenia—Methylprednisolone—multiple sclerosis	0.00015	0.00141	CcSEcCtD
Procainamide—Pruritus—Triamcinolone—multiple sclerosis	0.000149	0.00139	CcSEcCtD
Procainamide—Pruritus—Methylprednisolone—multiple sclerosis	0.000148	0.00139	CcSEcCtD
Procainamide—Convulsion—Methotrexate—multiple sclerosis	0.000147	0.00138	CcSEcCtD
Procainamide—Myalgia—Methotrexate—multiple sclerosis	0.000145	0.00136	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—multiple sclerosis	0.000145	0.00136	CcSEcCtD
Procainamide—Decreased appetite—Prednisone—multiple sclerosis	0.000144	0.00135	CcSEcCtD
Procainamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000143	0.00134	CcSEcCtD
Procainamide—Discomfort—Methotrexate—multiple sclerosis	0.000143	0.00134	CcSEcCtD
Procainamide—Confusional state—Methotrexate—multiple sclerosis	0.00014	0.00131	CcSEcCtD
Procainamide—Dizziness—Triamcinolone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Procainamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Procainamide—Feeling abnormal—Prednisone—multiple sclerosis	0.000137	0.00128	CcSEcCtD
Procainamide—Asthenia—Betamethasone—multiple sclerosis	0.000137	0.00128	CcSEcCtD
Procainamide—Asthenia—Dexamethasone—multiple sclerosis	0.000137	0.00128	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000136	0.00127	CcSEcCtD
Procainamide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000136	0.00127	CcSEcCtD
Procainamide—Nausea—Prednisolone—multiple sclerosis	0.000136	0.00127	CcSEcCtD
Procainamide—Pruritus—Betamethasone—multiple sclerosis	0.000135	0.00126	CcSEcCtD
Procainamide—Pruritus—Dexamethasone—multiple sclerosis	0.000135	0.00126	CcSEcCtD
Procainamide—Vomiting—Triamcinolone—multiple sclerosis	0.000134	0.00125	CcSEcCtD
Procainamide—Vomiting—Methylprednisolone—multiple sclerosis	0.000133	0.00125	CcSEcCtD
Procainamide—Anorexia—Methotrexate—multiple sclerosis	0.000132	0.00124	CcSEcCtD
Procainamide—Urticaria—Prednisone—multiple sclerosis	0.000132	0.00123	CcSEcCtD
Procainamide—Abdominal pain—Prednisone—multiple sclerosis	0.000131	0.00123	CcSEcCtD
Procainamide—Body temperature increased—Prednisone—multiple sclerosis	0.000131	0.00123	CcSEcCtD
Procainamide—Diarrhoea—Betamethasone—multiple sclerosis	0.00013	0.00122	CcSEcCtD
Procainamide—Diarrhoea—Dexamethasone—multiple sclerosis	0.00013	0.00122	CcSEcCtD
Procainamide—Hypotension—Methotrexate—multiple sclerosis	0.00013	0.00121	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000126	0.00118	CcSEcCtD
Procainamide—Dizziness—Dexamethasone—multiple sclerosis	0.000126	0.00118	CcSEcCtD
Procainamide—Dizziness—Betamethasone—multiple sclerosis	0.000126	0.00118	CcSEcCtD
Procainamide—Nausea—Triamcinolone—multiple sclerosis	0.000125	0.00117	CcSEcCtD
Procainamide—Nausea—Methylprednisolone—multiple sclerosis	0.000125	0.00117	CcSEcCtD
Procainamide—Hypersensitivity—Prednisone—multiple sclerosis	0.000122	0.00115	CcSEcCtD
Procainamide—Vomiting—Betamethasone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Procainamide—Vomiting—Dexamethasone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Procainamide—Asthenia—Prednisone—multiple sclerosis	0.000119	0.00112	CcSEcCtD
Procainamide—Pruritus—Prednisone—multiple sclerosis	0.000118	0.0011	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000114	0.00107	CcSEcCtD
Procainamide—Diarrhoea—Prednisone—multiple sclerosis	0.000114	0.00106	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000114	0.00106	CcSEcCtD
Procainamide—Nausea—Betamethasone—multiple sclerosis	0.000113	0.00106	CcSEcCtD
Procainamide—Nausea—Dexamethasone—multiple sclerosis	0.000113	0.00106	CcSEcCtD
Procainamide—Urticaria—Methotrexate—multiple sclerosis	0.00011	0.00103	CcSEcCtD
Procainamide—Dizziness—Prednisone—multiple sclerosis	0.00011	0.00103	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—multiple sclerosis	0.00011	0.00103	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—multiple sclerosis	0.00011	0.00103	CcSEcCtD
Procainamide—Vomiting—Prednisone—multiple sclerosis	0.000106	0.000988	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—multiple sclerosis	0.000102	0.000957	CcSEcCtD
Procainamide—Asthenia—Methotrexate—multiple sclerosis	9.96e-05	0.000932	CcSEcCtD
Procainamide—Nausea—Prednisone—multiple sclerosis	9.87e-05	0.000923	CcSEcCtD
Procainamide—Pruritus—Methotrexate—multiple sclerosis	9.82e-05	0.000919	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—multiple sclerosis	9.5e-05	0.000889	CcSEcCtD
Procainamide—Dizziness—Methotrexate—multiple sclerosis	9.18e-05	0.000859	CcSEcCtD
Procainamide—Vomiting—Methotrexate—multiple sclerosis	8.83e-05	0.000826	CcSEcCtD
Procainamide—Nausea—Methotrexate—multiple sclerosis	8.24e-05	0.000772	CcSEcCtD
Procainamide—SCN5A—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.34e-05	0.00065	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—STAT3—multiple sclerosis	4.33e-05	0.000648	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CYP27B1—multiple sclerosis	4.3e-05	0.000644	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CYP24A1—multiple sclerosis	4.3e-05	0.000644	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—S1PR1—multiple sclerosis	4.28e-05	0.000641	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—CCL5—multiple sclerosis	4.25e-05	0.000637	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—IL6—multiple sclerosis	4.23e-05	0.000634	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.2e-05	0.00063	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—TNF—multiple sclerosis	4.2e-05	0.000629	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—TYK2—multiple sclerosis	4.2e-05	0.000629	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—TYK2—multiple sclerosis	4.2e-05	0.000629	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	4.17e-05	0.000624	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—RRM1—multiple sclerosis	4.14e-05	0.00062	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—MAPK1—multiple sclerosis	4.08e-05	0.000611	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—TYK2—multiple sclerosis	4.05e-05	0.000607	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—TYK2—multiple sclerosis	4.05e-05	0.000607	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—TGFB1—multiple sclerosis	4.01e-05	0.000601	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—TYK2—multiple sclerosis	3.99e-05	0.000598	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CCL3—multiple sclerosis	3.98e-05	0.000596	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—STAT3—multiple sclerosis	3.96e-05	0.000593	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GPC5—multiple sclerosis	3.93e-05	0.000589	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MAPK1—multiple sclerosis	3.93e-05	0.000589	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	3.93e-05	0.000588	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—MAPK1—multiple sclerosis	3.9e-05	0.000584	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—S1PR1—multiple sclerosis	3.89e-05	0.000583	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.88e-05	0.000582	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—IL6—multiple sclerosis	3.87e-05	0.00058	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CYP27B1—multiple sclerosis	3.84e-05	0.000575	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CYP24A1—multiple sclerosis	3.84e-05	0.000575	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—PTGER4—multiple sclerosis	3.83e-05	0.000574	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—CCR5—multiple sclerosis	3.83e-05	0.000574	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MAPK1—multiple sclerosis	3.75e-05	0.000561	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MAPK1—multiple sclerosis	3.75e-05	0.000561	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—TNF—multiple sclerosis	3.74e-05	0.000561	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CXCR3—multiple sclerosis	3.7e-05	0.000554	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—TGFB1—multiple sclerosis	3.67e-05	0.000549	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—RGS1—multiple sclerosis	3.64e-05	0.000545	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—BCHE—multiple sclerosis	3.63e-05	0.000544	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—MAPK1—multiple sclerosis	3.61e-05	0.000541	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MAPK1—multiple sclerosis	3.61e-05	0.000541	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CCR2—multiple sclerosis	3.6e-05	0.000539	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MMP9—multiple sclerosis	3.6e-05	0.000539	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MAPK1—multiple sclerosis	3.6e-05	0.000539	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	3.55e-05	0.000533	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GPC5—multiple sclerosis	3.51e-05	0.000526	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.5e-05	0.000524	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GPR65—multiple sclerosis	3.45e-05	0.000517	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MMP9—multiple sclerosis	3.44e-05	0.000516	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CYP24A1—multiple sclerosis	3.43e-05	0.000513	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CYP27B1—multiple sclerosis	3.43e-05	0.000513	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—TNF—multiple sclerosis	3.42e-05	0.000513	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—IL6—multiple sclerosis	3.39e-05	0.000508	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	3.38e-05	0.000507	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CNR1—multiple sclerosis	3.32e-05	0.000498	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MMP9—multiple sclerosis	3.31e-05	0.000495	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MMP9—multiple sclerosis	3.31e-05	0.000495	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—RGS1—multiple sclerosis	3.31e-05	0.000495	CbGpPWpGaD
Procainamide—ACHE—Metabolism—RRM1—multiple sclerosis	3.26e-05	0.000488	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—STAT3—multiple sclerosis	3.2e-05	0.000479	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CYP27B1—multiple sclerosis	3.19e-05	0.000479	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CYP24A1—multiple sclerosis	3.19e-05	0.000479	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MMP9—multiple sclerosis	3.19e-05	0.000478	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MMP9—multiple sclerosis	3.19e-05	0.000478	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.17e-05	0.000475	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCL13—multiple sclerosis	3.16e-05	0.000473	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CCR1—multiple sclerosis	3.16e-05	0.000473	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MMP9—multiple sclerosis	3.14e-05	0.000471	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GPR65—multiple sclerosis	3.13e-05	0.00047	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GPC5—multiple sclerosis	3.13e-05	0.00047	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—IL6—multiple sclerosis	3.13e-05	0.000469	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	3.08e-05	0.000462	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—STAT3—multiple sclerosis	3.06e-05	0.000458	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.05e-05	0.000456	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—LINGO1—multiple sclerosis	3.03e-05	0.000454	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—IL6—multiple sclerosis	3.02e-05	0.000453	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.01e-05	0.000451	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3e-05	0.000449	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—IL6—multiple sclerosis	3e-05	0.000449	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—POMC—multiple sclerosis	2.99e-05	0.000449	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CXCL10—multiple sclerosis	2.99e-05	0.000448	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—TGFB1—multiple sclerosis	2.97e-05	0.000444	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.95e-05	0.000442	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.94e-05	0.000441	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—STAT3—multiple sclerosis	2.94e-05	0.00044	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—STAT3—multiple sclerosis	2.94e-05	0.00044	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GPC5—multiple sclerosis	2.92e-05	0.000438	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MAPK1—multiple sclerosis	2.91e-05	0.000436	CbGpPWpGaD
Procainamide—BCHE—Metabolism—RRM1—multiple sclerosis	2.91e-05	0.000436	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—IL6—multiple sclerosis	2.88e-05	0.000431	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—IL6—multiple sclerosis	2.88e-05	0.000431	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCR1—multiple sclerosis	2.87e-05	0.000429	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCL13—multiple sclerosis	2.87e-05	0.000429	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—TYK2—multiple sclerosis	2.85e-05	0.000426	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—TGFB1—multiple sclerosis	2.84e-05	0.000425	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.84e-05	0.000425	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—STAT3—multiple sclerosis	2.83e-05	0.000425	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—STAT3—multiple sclerosis	2.83e-05	0.000425	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.8e-05	0.00042	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MAPK1—multiple sclerosis	2.78e-05	0.000417	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—IL6—multiple sclerosis	2.77e-05	0.000416	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—IL6—multiple sclerosis	2.77e-05	0.000416	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—TNF—multiple sclerosis	2.77e-05	0.000415	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—IL6—multiple sclerosis	2.76e-05	0.000414	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.75e-05	0.000412	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—TGFB1—multiple sclerosis	2.73e-05	0.000408	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—TGFB1—multiple sclerosis	2.73e-05	0.000408	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MAPK1—multiple sclerosis	2.67e-05	0.0004	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MAPK1—multiple sclerosis	2.67e-05	0.0004	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—TNF—multiple sclerosis	2.65e-05	0.000397	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—TGFB1—multiple sclerosis	2.63e-05	0.000394	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—TGFB1—multiple sclerosis	2.63e-05	0.000394	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TAGAP—multiple sclerosis	2.63e-05	0.000394	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—RRM1—multiple sclerosis	2.6e-05	0.000389	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MAPK1—multiple sclerosis	2.58e-05	0.000386	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MAPK1—multiple sclerosis	2.58e-05	0.000386	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CCL5—multiple sclerosis	2.57e-05	0.000386	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—TNF—multiple sclerosis	2.54e-05	0.000381	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—TNF—multiple sclerosis	2.54e-05	0.000381	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MAPK1—multiple sclerosis	2.54e-05	0.00038	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.53e-05	0.000379	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.53e-05	0.000379	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SRM—multiple sclerosis	2.5e-05	0.000375	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—TNF—multiple sclerosis	2.45e-05	0.000368	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—TNF—multiple sclerosis	2.45e-05	0.000368	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	2.44e-05	0.000365	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—RRM1—multiple sclerosis	2.42e-05	0.000363	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.39e-05	0.000358	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.38e-05	0.000357	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.38e-05	0.000357	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—BCHE—multiple sclerosis	2.38e-05	0.000356	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.33e-05	0.000349	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.32e-05	0.000348	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CCR5—multiple sclerosis	2.32e-05	0.000347	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—S1PR1—multiple sclerosis	2.3e-05	0.000344	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.26e-05	0.000338	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.26e-05	0.000338	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP9—multiple sclerosis	2.24e-05	0.000336	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—TNF—multiple sclerosis	2.24e-05	0.000335	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—IL6—multiple sclerosis	2.23e-05	0.000335	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GPC5—multiple sclerosis	2.23e-05	0.000335	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—MAPK1—multiple sclerosis	2.17e-05	0.000325	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.17e-05	0.000325	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PTGER4—multiple sclerosis	2.17e-05	0.000324	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—IL6—multiple sclerosis	2.14e-05	0.00032	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.11e-05	0.000315	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCR3—multiple sclerosis	2.09e-05	0.000313	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—IL6—multiple sclerosis	2.05e-05	0.000308	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—IL6—multiple sclerosis	2.05e-05	0.000308	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCL3—multiple sclerosis	2.04e-05	0.000306	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CCR2—multiple sclerosis	2.03e-05	0.000305	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—STAT3—multiple sclerosis	1.99e-05	0.000299	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.98e-05	0.000297	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—IL6—multiple sclerosis	1.98e-05	0.000297	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—IL6—multiple sclerosis	1.98e-05	0.000297	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTGER4—multiple sclerosis	1.97e-05	0.000295	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RGS1—multiple sclerosis	1.95e-05	0.000293	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—IL6—multiple sclerosis	1.95e-05	0.000292	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—MAPK1—multiple sclerosis	1.94e-05	0.00029	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.94e-05	0.00029	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCR3—multiple sclerosis	1.9e-05	0.000284	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CNR1—multiple sclerosis	1.88e-05	0.000281	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—POMC—multiple sclerosis	1.88e-05	0.000281	CbGpPWpGaD
Procainamide—ACHE—Metabolism—BCHE—multiple sclerosis	1.87e-05	0.00028	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GPR65—multiple sclerosis	1.85e-05	0.000277	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—TGFB1—multiple sclerosis	1.85e-05	0.000277	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCR2—multiple sclerosis	1.85e-05	0.000277	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—CCL2—multiple sclerosis	1.84e-05	0.000275	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—POMC—multiple sclerosis	1.81e-05	0.000272	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MAPK1—multiple sclerosis	1.81e-05	0.000271	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	1.81e-05	0.000271	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CCL2—multiple sclerosis	1.77e-05	0.000266	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.77e-05	0.000265	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.76e-05	0.000264	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.76e-05	0.000264	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—MYC—multiple sclerosis	1.75e-05	0.000262	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—MAPK1—multiple sclerosis	1.73e-05	0.000259	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—TNF—multiple sclerosis	1.73e-05	0.000258	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CNR1—multiple sclerosis	1.7e-05	0.000255	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCR1—multiple sclerosis	1.69e-05	0.000254	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL13—multiple sclerosis	1.69e-05	0.000254	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCL10—multiple sclerosis	1.69e-05	0.000253	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—POMC—multiple sclerosis	1.67e-05	0.000251	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—CCL2—multiple sclerosis	1.64e-05	0.000245	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—MAPK1—multiple sclerosis	1.61e-05	0.000242	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.61e-05	0.000242	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCL10—multiple sclerosis	1.53e-05	0.00023	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.5e-05	0.000225	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—BCHE—multiple sclerosis	1.49e-05	0.000223	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CCL5—multiple sclerosis	1.45e-05	0.000218	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—APOE—multiple sclerosis	1.43e-05	0.000214	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.4e-05	0.00021	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—IL6—multiple sclerosis	1.39e-05	0.000209	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—BCHE—multiple sclerosis	1.39e-05	0.000208	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.34e-05	0.0002	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCL5—multiple sclerosis	1.32e-05	0.000198	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CCR5—multiple sclerosis	1.31e-05	0.000196	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2RA—multiple sclerosis	1.29e-05	0.000194	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—POMC—multiple sclerosis	1.23e-05	0.000184	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCL3—multiple sclerosis	1.21e-05	0.000181	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCR5—multiple sclerosis	1.19e-05	0.000178	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2RA—multiple sclerosis	1.17e-05	0.000176	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTGER4—multiple sclerosis	1.16e-05	0.000174	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PGR—multiple sclerosis	1.14e-05	0.000171	CbGpPWpGaD
Procainamide—ACHE—Metabolism—APOE—multiple sclerosis	1.13e-05	0.000169	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCR3—multiple sclerosis	1.12e-05	0.000168	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ALB—multiple sclerosis	1.12e-05	0.000168	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CD28—multiple sclerosis	1.11e-05	0.000166	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCR2—multiple sclerosis	1.09e-05	0.000163	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—POMC—multiple sclerosis	1.02e-05	0.000153	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CNR1—multiple sclerosis	1.01e-05	0.000151	CbGpPWpGaD
Procainamide—BCHE—Metabolism—APOE—multiple sclerosis	1e-05	0.000151	CbGpPWpGaD
Procainamide—ACHE—Metabolism—POMC—multiple sclerosis	9.67e-06	0.000145	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—POMC—multiple sclerosis	9.3e-06	0.000139	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCL2—multiple sclerosis	9.1e-06	0.000136	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL10—multiple sclerosis	9.07e-06	0.000136	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—APOE—multiple sclerosis	8.97e-06	0.000134	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ALB—multiple sclerosis	8.82e-06	0.000132	CbGpPWpGaD
Procainamide—BCHE—Metabolism—POMC—multiple sclerosis	8.63e-06	0.000129	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—APOE—multiple sclerosis	8.36e-06	0.000125	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—TYK2—multiple sclerosis	8.27e-06	0.000124	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CD86—multiple sclerosis	7.93e-06	0.000119	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ALB—multiple sclerosis	7.87e-06	0.000118	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCL5—multiple sclerosis	7.8e-06	0.000117	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—POMC—multiple sclerosis	7.71e-06	0.000115	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—BCHE—multiple sclerosis	7.68e-06	0.000115	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2—multiple sclerosis	7.57e-06	0.000113	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SPP1—multiple sclerosis	7.23e-06	0.000108	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—POMC—multiple sclerosis	7.18e-06	0.000108	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCR5—multiple sclerosis	7.03e-06	0.000105	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ALB—multiple sclerosis	7.03e-06	0.000105	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2RA—multiple sclerosis	6.93e-06	0.000104	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2—multiple sclerosis	6.88e-06	0.000103	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ALB—multiple sclerosis	6.55e-06	9.81e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—APOE—multiple sclerosis	6.4e-06	9.58e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CD80—multiple sclerosis	5.78e-06	8.67e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—POMC—multiple sclerosis	5.5e-06	8.23e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCL2—multiple sclerosis	5.38e-06	8.06e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MAPK1—multiple sclerosis	5.26e-06	7.88e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TYK2—multiple sclerosis	4.88e-06	7.32e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—APOE—multiple sclerosis	4.62e-06	6.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2—multiple sclerosis	4.06e-06	6.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6—multiple sclerosis	4.04e-06	6.06e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—POMC—multiple sclerosis	3.97e-06	5.95e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—multiple sclerosis	3.85e-06	5.76e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ALB—multiple sclerosis	3.62e-06	5.42e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT3—multiple sclerosis	3.42e-06	5.12e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—multiple sclerosis	3.18e-06	4.76e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TGFB1—multiple sclerosis	3.17e-06	4.75e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK1—multiple sclerosis	3.11e-06	4.66e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6—multiple sclerosis	2.39e-06	3.58e-05	CbGpPWpGaD
